A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult chinese patients with treatment-resistant major depression

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 638-642

  Fang, Yiru ^a   Yuan, Chengmei ^a   Xu, Yifeng ^a   Chen, Jun ^a   Wu, Zhiguo ^a   Cao, Lan ^a   Yi, Zhenghui ^a   Hong, Wu ^a   Wang, Yong ^a   Jiang, Kaida ^a   Cui, Xingjia ^b   Calabrese, Joseph R ^c   Gao, Keming ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

augmentation; buspirone; risperidone; sodium valproate; thyroid hormone; trazodone; Treatment resistant depression

Indexed keywords

BUSPIRONE; PAROXETINE; PLACEBO; RISPERIDONE; THYROID HORMONE; TRAZODONE; VALPROIC ACID;

ADULT; AGED; ANOREXIA; ARTICLE; CHINESE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAMILTON SCALE; HUMAN; LIFE SATISFACTION RATING SCALE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NAUSEA AND VOMITING; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; SELF RATING DEPRESSION SCALE; SHORT FORM 36; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT; XEROSTOMIA;

BUSPIRONE; CHINA; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PAROXETINE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS; THYROID HORMONES; TRAZODONE; VALPROIC ACID;

EID: 80052471790     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822bb1d9     Document Type: Article

References (19)

1. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res. 2002;53:849-857. (Pubitemid 35282613)
2. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53:743-753. (Pubitemid 39658488)
3. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63: 826-837.
4. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649-659. (Pubitemid 39658481)
5. Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of evidence. CNS Spectr. 2004;9: 808-821. (Pubitemid 39602937)
6. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65:341-347.
7. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(suppl 18):12-17. (Pubitemid 33736200)
8. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 18):4-11. (Pubitemid 33736199)
9. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006;75:139-153.
10. Nierenberg AA, Ostacher MJ, Huffman JC, et al. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med. 2008;50: 428-436. (Pubitemid 351521617)
11. Appelberg BG, Syvälahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62:448-452. (Pubitemid 32717878)
12. Fang YR, Yuan CM, Xu YF, et al. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression a double-blind, randomized pilot study in a Chinese population. J Clin Psychopharmaco. 2010;30: 357-364.
13. Zhang MY. Manual for Psychiatric Rating Scale. 1st ed. Changsha, Hunan, China: Hunan Science and Technology Press; 1998.
14. Cheng JJ, Ho H, Chang CJ, et al. Positive and Negative Syndrome Scale (PANSS): establishment and reliability study of a Mandarin Chinese language version. Chinese Psychiatry. 1996;10: 251-258.
15. Wang XD. Manual for psychological rating scale. Chin Mental Health J 1999;(suppl 131-133):76-78.
16. Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Harv Rev Psychiatry. 2009;17: 231-241.
17. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147:593-562.
18. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31:2505-2513. (Pubitemid 44607069)
19. Shelton RC, Osuntokun O, Heinloth AN, et al. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24:131-161.